Page last updated: 2024-12-06
febarbamate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Febarbamate is a GABAergic anticonvulsant that was initially synthesized as a barbiturate analog. It acts by enhancing the inhibitory effects of GABA in the central nervous system. Febarbamate has been studied for its potential efficacy in treating various neurological conditions, including epilepsy, anxiety, and muscle spasms. The mechanism of action of Febarbamate involves binding to GABA receptors and increasing the frequency of chloride ion channel opening, leading to hyperpolarization of neurons. Febarbamate has demonstrated significant anticonvulsant activity in both preclinical and clinical studies, and it has been used in the treatment of generalized tonic-clonic seizures and partial seizures. However, due to its sedative side effects and potential for drug interactions, its use has declined in recent years. Febarbamate continues to be studied for its potential in treating specific types of epilepsy, particularly in cases where other medications have failed. Research is ongoing to explore its potential therapeutic benefits and to understand its mechanisms of action in more detail.'
febarbamate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 25803 |
| CHEMBL ID | 2104283 |
| CHEBI ID | 135655 |
| SCHEMBL ID | 18473 |
| MeSH ID | M0044032 |
Synonyms (39)
| Synonym |
|---|
| D07275 |
| 13246-02-1 |
| febarbamate (inn) |
| febarbamatum [inn-latin] |
| tymium |
| einecs 236-226-3 |
| g-tril |
| 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid carbamate ester |
| carbamic acid, ester with 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid |
| 3-(3-butoxy-3-carbamoyloxypropyl)-5-ethyl-5-phenylbarbituric acid |
| 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid, carbamate ester |
| 3-(gamma-butoxy-beta-carbamyl-beta-propanol)-5-phenyl-5-ethylmalonylurea |
| febarbamate |
| febarbamate [inn:dcf] |
| go 560 |
| brn 0591584 |
| barbituric acid, 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenyl-, carbamate (ester) |
| phebarbamate |
| phenobamate |
| febarbamato [inn-spanish] |
| getril |
| CHEBI:135655 |
| [1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl] carbamate |
| febarbamatum |
| 5z48onn38p , |
| go-560 |
| unii-5z48onn38p |
| febarbamato |
| 5-24-09-00304 (beilstein handbook reference) |
| febarbamate [who-dd] |
| febarbamate [mi] |
| febarbamate [inn] |
| febarbamate [mart.] |
| CHEMBL2104283 |
| SCHEMBL18473 |
| Q5439707 |
| DB13303 |
| 1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl carbamate |
| DTXSID40864380 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| barbiturates | Members of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||